Literature DB >> 25140698

Why the product labeling for low-dose vaginal estrogen should be changed.

JoAnn E Manson1, Steven R Goldstein, Risa Kagan, Andrew M Kaunitz, James H Liu, JoAnn V Pinkerton, Robert W Rebar, Peter F Schnatz, Jan L Shifren, Cynthia A Stuenkel, Margery L S Gass, Wulf H Utian.   

Abstract

Mesh：

Substances：

Year:  2014        PMID： 25140698     DOI： 10.1097/GME.0000000000000316

Source DB:  PubMed          Journal:  Menopause        ISSN： 1072-3714            Impact factor:   2.953


× No keyword cloud information.
  13 in total

1.  Vaginal estrogen use and chronic disease risk in the Nurses' Health Study.

Authors:  Shilpa N Bhupathiraju; Francine Grodstein; Meir J Stampfer; Walter C Willett; Carolyn J Crandall; Jan L Shifren; JoAnn E Manson
Journal:  Menopause       Date:  2018-12-17       Impact factor: 2.953

2.  Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women's Health Initiative Observational Study.

Authors:  Carolyn J Crandall; Kathleen M Hovey; Christopher A Andrews; Rowan T Chlebowski; Marcia L Stefanick; Dorothy S Lane; Jan Shifren; Chu Chen; Andrew M Kaunitz; Jane A Cauley; JoAnn E Manson
Journal:  Menopause       Date:  2018-01       Impact factor: 2.953

Review 3.  A clinical guide to the management of genitourinary symptoms in breast cancer survivors on endocrine therapy.

Authors:  Mariana S Sousa; Michelle Peate; Sherin Jarvis; Martha Hickey; Michael Friedlander
Journal:  Ther Adv Med Oncol       Date:  2017-01-31       Impact factor: 8.168

4.  Pharmacokinetic studies of solubilized estradiol given vaginally in a novel softgel capsule.

Authors:  J H Pickar; J M Amadio; B A Bernick; S Mirkin
Journal:  Climacteric       Date:  2016-02-09       Impact factor: 3.005

5.  The REJOICE trial: a phase 3 randomized, controlled trial evaluating the safety and efficacy of a novel vaginal estradiol soft-gel capsule for symptomatic vulvar and vaginal atrophy.

Authors:  Ginger D Constantine; James A Simon; James H Pickar; David F Archer; Harvey Kushner; Brian Bernick; Gina Gasper; Shelli Graham; Sebastian Mirkin
Journal:  Menopause       Date:  2017-04       Impact factor: 2.953

6.  Female Sexual Health: Barriers to Optimal Outcomes and a Roadmap for Improved Patient-Clinician Communications.

Authors:  Sheryl A Kingsberg; Jonathan Schaffir; Brooke M Faught; JoAnn V Pinkerton; Sharon J Parish; Cheryl B Iglesia; Jennifer Gudeman; Julie Krop; James A Simon
Journal:  J Womens Health (Larchmt)       Date:  2019-02-04       Impact factor: 2.681

7.  WISDOM survey: attitudes and behaviors of physicians toward vulvar and vaginal atrophy (VVA) treatment in women including those with breast cancer history.

Authors:  Sheryl A Kingsberg; Lisa Larkin; Michael Krychman; Sharon J Parish; Brian Bernick; Sebastian Mirkin
Journal:  Menopause       Date:  2019-02       Impact factor: 2.953

Review 8.  Practical Treatment Considerations in the Management of Genitourinary Syndrome of Menopause.

Authors:  Risa Kagan; Susan Kellogg-Spadt; Sharon J Parish
Journal:  Drugs Aging       Date:  2019-10       Impact factor: 3.923

9.  A randomized, double-blind, placebo-controlled phase 2 pilot trial evaluating a novel, vaginal softgel capsule containing solubilized estradiol.

Authors:  James H Pickar; Julia M Amadio; John M Hill; Brian A Bernick; Sebastian Mirkin
Journal:  Menopause       Date:  2016-05       Impact factor: 2.953

10.  Overall Safety of Ospemifene in Postmenopausal Women from Placebo-Controlled Phase 2 and 3 Trials.

Authors:  James A Simon; Corrado Altomare; Susannah Cort; Wei Jiang; JoAnn V Pinkerton
Journal:  J Womens Health (Larchmt)       Date:  2017-10-24       Impact factor: 2.681
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.